Apolipoprotein E (APOE) plays a critical role in lipid transport and metabolism in the brain, and common genetic variants of APOE represent the strongest known risk factor for late-onset Alzheimer's disease (AD). The APOE ε4 allele increases AD risk by 3-4 fold in heterozygotes and 12-15 fold in homozygotes, while the ε2 allele appears to be protective 1. This pathway page explores the molecular mechanisms by which APOE influences lipid metabolism, amyloid processing, tau pathology, neuroinflammation, and synaptic function in AD.
¶ The APOE Gene and Protein
The APOE gene has three common alleles (ε2, ε3, ε4) that encode different protein isoforms:
| Allele |
Frequency |
Effect on AD Risk |
| ε2 |
~8% |
Protective (OR ~0.6) |
| ε3 |
~78% |
Baseline risk |
| ε4 |
~14% |
Risk (OR ~3-4 for heterozygotes) |
The amino acid substitutions are:
- APOE ε2 (Cys130, Cys176): Arg130→Cys, Arg176→Cys
- APOE ε3 (Cys130, Arg176): Most common isoform
- APOE ε4 (Arg130, Arg176): Cys130→Arg
In the central nervous system, APOE is primarily produced by astrocytes and microglia, with neurons expressing APOE under stress conditions 2. APOE is the principal lipoprotein in the brain, synthesized locally and essential for cholesterol and phospholipid transport between cells.
¶ Pathway: APOE in Lipid Transport and Cholesterol Homeostasis
flowchart TD
A[Cholesterol] --> B[Astrocytes synthesize APOE]
B --> C[APOE secreted as lipoprotein particle]
C --> D[APOE binds to LDL Receptor Family]
D --> E[LDLR - Low Density Lipoprotein Receptor]
D --> F[LRP1 - LDL Receptor-Related Protein 1]
D --> G[LDLRAP1 - LDLR Adapter Protein]
E --> H[Neuron cholesterol uptake]
F --> H
G --> H
H --> I[Synaptic function & membrane maintenance]
J[APOE ε4] --> K[Reduced lipid binding capacity]
K --> L[Impaired cholesterol delivery to neurons]
L --> M[Synaptic dysfunction]
M --> N[Neurodegeneration]
J --> O[Conformation changes]
O --> P[Domain interaction]
P --> Q[Increased aggregation propensity]
Q --> R[Amyloid co-deposition]
- Synthesis: Astrocytes synthesize and secrete APOE as part of lipoparticles (HDL-like particles)
- Lipidation: APOE requires lipidation by ATP-binding cassette transporters (ABCA1, ABCG1) to function properly
- Receptor binding: APOE binds to multiple receptors including LDLR, LRP1, and HSPG
- Cellular uptake: Bound APOE-lipoprotein complexes are internalized
- Cholesterol delivery: Lipids are delivered to neurons for membrane synthesis and repair
The ATP-binding cassette transporters ABCA1 and ABCG1 are critical for APOE lipidation:
- ABCA1 mediates the initial lipidation of APOE, transferring cholesterol and phospholipids to the nascent APOE particle 3
- ABCG1 further enriches the lipid content, particularly in neurons
- Deficiency in ABCA1 leads to poorly lipidated APOE with reduced functionality
¶ Pathway: APOE and Amyloid Processing
APOE significantly influences amyloid-beta (Aβ) metabolism through multiple mechanisms:
flowchart TD
A[APP] --> B[BACE1 cleavage]
B --> C[sAPPβ]
C --> D[γ-secretase cleavage]
D --> E[Aβ peptides]
F[APOE] --> G[Binds to Aβ]
G --> H[APOE-Aβ complex formation]
H --> I[Clearance pathways]
I --> J[LRP1-mediated clearance]
I --> K[LDLR-mediated clearance]
I --> L[HSPG-mediated clearance]
M[APOE ε4] --> N[Reduced Aβ clearance]
N --> O[Increased Aβ aggregation]
O --> P[Accelerated plaque deposition]
M --> Q[Enhanced Aβ production]
Q --> P
E --> P
- Direct binding: APOE directly binds to Aβ with isoform-dependent affinity (ε4 > ε3 > ε2) 4
- Clearance modulation: APOE-Aβ complexes are cleared via LRP1 and LDLR
- Aggregation seeding: APOE ε4 promotes Aβ aggregation and plaque formation
- Production effects: APOE can influence Aβ production through APP trafficking
- APOE ε4: Poor lipid binding, enhanced Aβ binding, reduced clearance, promotes plaque formation
- APOE ε3: Intermediate function, efficient lipid binding, normal Aβ clearance
- APOE ε2: Best lipid binding, reduced Aβ binding, enhanced clearance (protective)
¶ Pathway: APOE and Neuroinflammation
APOE plays a complex role in modulating neuroinflammation:
flowchart TD
A[APOE] --> B[Microglial signaling]
B --> C[TREM2 activation]
C --> D[TYROBP signaling]
D --> E[Phagocytosis]
F[APOE ε4] --> G[Dysregulated inflammatory response]
G --> H[Increased cytokine production]
H --> I[IL-1β, IL-6, TNF-α]
I --> J[Chronic neuroinflammation]
F --> K[Impaired Aβ clearance]
K --> L[Persistent Aβ accumulation]
L --> J
J --> M[Neuronal dysfunction]
M --> N[Synaptic loss]
¶ APOE and TREM2 Signaling
The interaction between APOE and TREM2 is crucial for microglial function:
- TREM2 (Triggering receptor expressed on myeloid cells 2) is a major AD risk gene
- APOE is a ligand for TREM2 5
- APOE ε4 leads to reduced TREM2 signaling and impaired microglial phagocytosis
- This creates a feed-forward loop: poor Aβ clearance → increased inflammation → more APOE production
¶ Pathway: APOE and Synaptic Function
APOE is essential for synaptic maintenance and plasticity:
flowchart TD
A[Synaptic activity] --> B[Increased cholesterol demand]
B --> C[APOE-mediated lipid delivery]
C --> D[Synaptic vesicle recycling]
D --> E[Neurotransmitter release]
F[APOE ε4] --> G[Impaired lipid delivery]
G --> H[Reduced synaptic vesicle pools]
H --> I[Synaptic dysfunction]
I --> J[Memory deficits]
F --> K[Direct synaptic toxicity]
K --> I
- Cholesterol delivery: Synaptic membranes require cholesterol for proper function
- Receptor trafficking: APOE influences NMDA receptor and AMPA receptor trafficking
- Dendritic spine maintenance: APOE ε4 is associated with reduced dendritic spine density
- Long-term potentiation: APOE ε4 impairs LTP in animal models 6
¶ Pathway: APOE in Tau Pathology and Neurodegeneration
APOE also influences tau pathology through both direct and indirect mechanisms:
flowchart TD
A[APOE ε4] --> B[Impaired neuronal function]
B --> C[Cellular stress]
C --> D[Tau kinase activation]
D --> E[GSK3β, CDK5]
E --> F[Tau hyperphosphorylation]
F --> G[NFT formation]
A --> H[Enhanced neuroinflammation]
H --> I[Microglial activation]
I --> J[Cytokine release]
J --> D
G --> K[Neuronal loss]
K --> L[Brain atrophy]
- APOE modulators: Small molecules that shift APOE ε4 conformation toward ε3-like state
- Gene therapy: AAV-mediated APOE ε2 expression in APOE ε4 homozygotes
- ABCA1 agonists: Enhance APOE lipidation and function
- Peptide mimetics: APOE-derived peptides that preserve protective functions
| Approach |
Status |
Description |
| AAV-APOE2 |
Phase 1/2 |
Gene therapy delivering APOE ε2 |
| ABCA1 modulators |
Preclinical |
Enhance APOE lipidation |
| Anti-APOE antibodies |
Preclinical |
Neutralize toxic APOE fragments |
- APOE ε4 allele and the risk of Alzheimer's disease (1993)
- Astrocyte-specific expression of APOE in the brain (2010)
- ABCA1 mediates APOE lipidation (2003)
- APOE binds to Aβ with isoform-dependent affinity (1994)
- APOE is a ligand for TREM2 (2016)
- APOE ε4 impairs LTP in transgenic mice (2000)